May 12, 2026 | Congress, Pharma, healthcare
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize the value of congress investment and deliver measurable business impact.

Medical congresses remain one of the most critical data milestones in an asset’s development, providing valuable opportunities to translate scientific innovation into clinical practice. However, many organizations still approach congresses as standalone events, with fragmented planning across therapy area teams, limited alignment to overarching disease area objectives, and limited clarity on measuring success beyond immediate metrics.
By operating as a single, integrated partner across the full data and congress lifecycle, Inizio helps clients navigate complexity, align stakeholders, and gain clearer confidence in the impact of their congress investments. Our strength lies in an unmatched vantage point – combining deep, cross-functional expertise with end-to-end visibility across the product lifecycle.
Intelligent Congress is built on this foundation. Drawing on more than 30 years of experience across therapy areas, it unites strategy, experience design, delivery, and measurement into one cohesive model. This depth and breadth enable clients to move beyond fragmented, activity-based metrics and instead focus on what truly matters – meaningful shifts in HCP understanding, engagement, and behavior.
Discover how Intelligent Congress can help you create more strategic, measurable, and impactful HCP engagement. Visit our congress page or connect with the Inizio team at booth 21157 during the ASCO® Annual Meeting 2026 to see Intelligent Congress in action.
Read full article here.
This content was provided by Inizio
Latest Content from Inizio
Watch our short video to see how we have grown. Please note the video comes with some fun, themed music. https://www.researchpartnership.com/news/2017/06/research-partnership-is-celebrating-20-years-in-bus…
This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in…
Research Partnership is delighted to welcome Anne Cunningham and Morten Andersen and announce that Sue Rees has joined our specialist Emerging Markets team.
We are delighted to be presenting a paper and exhibiting at the Pharmaceutical Market Research Conference 13-14 June in Bay Area close to our new office in San Francisco.Representing Research…
Visit us on stand number 14
We are delighted to announce that Research Partnership’s Director Richard Head has been nominated for The EphMRA President’s Award for Contribution to Pharmaceutical Market Research.According to EphMRA, Richard has been…
Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase…
Join us at EULAR Congress 2017 in Madrid, 14-17 June
Pegasus, an Ashfield company, part of UDG Healthcare plc, has unveiled a new brand identity signaling its successful integration with the global business, a year on from acquisition. Conceived by…
